News Headlines Article

FDA approves generic versions of antipsychotic drug Abilify

The U.S. Food and Drug Administration said it approved the first copycat versions of Otsuka Pharmaceutical Co Ltd’s antipsychotic drug, Abilify.

The FDA said on Tuesday that it had granted approval for generic versions of Abilify from four companies, including Teva Pharmaceutical Industries Ltd, to treat mental illnesses such as bipolar disorder and schizophrenia.

Abilify has an orphan drug designation for the treatment of Tourette’s syndrome, a nervous system disorder, in children.